Stoke Therapeutics Reports Strong 2025 Financials with Reduced Net Loss and Pipeline Advancement

summarizeSummary

Stoke Therapeutics reported a significant reduction in net loss and a substantial increase in revenue for 2025, extending its cash runway into 2028, alongside continued clinical progress for its lead drug candidates.

check_boxKey Events

• Significant Financial Improvement in 2025

  The company reported a net loss of $6.9 million for the year ended December 31, 2025, a substantial improvement from a net loss of $89.0 million in 2024. Revenue surged to $184.4 million in 2025 from $36.6 million in 2024, primarily driven by the Biogen collaboration.

• Extended Cash Runway into 2028

  Stoke Therapeutics ended 2025 with $390.9 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into 2028.

• Advancement of Lead Clinical Programs

  The global Phase 3 EMPEROR study for zorevunersen (STK-001) in Dravet syndrome initiated in May 2025, with enrollment expected to complete in Q2 2026 and pivotal data anticipated in mid-2027. The Phase 1 OSPREY study for STK-002 in Autosomal Dominant Optic Atrophy (ADOA) dosed its first patient in February 2026.

• Acadia Collaboration Program Terminations

  Acadia Pharmaceuticals Inc. terminated the MECP2 and an undisclosed neurodevelopmental program effective September 3, 2025, resulting in Stoke Therapeutics losing eligibility for up to $662.5 million in potential milestones from these programs. The SYNGAP1 collaboration with Acadia remains ongoing.

auto_awesomeAnalysis

Stoke Therapeutics' 2025 annual report highlights a significant financial turnaround, driven by a substantial increase in revenue and a dramatic reduction in net loss. The company's cash position provides a solid runway into 2028, supporting ongoing clinical development for its lead programs. While the termination of certain Acadia collaboration programs is a setback, the progress in the Phase 3 EMPEROR study for Dravet syndrome and the initiation of the Phase 1 OSPREY study for ADOA demonstrate continued pipeline advancement. The adoption of multiple Rule 10b5-1 plans by insiders is a notable, albeit pre-planned, selling signal.